Revolution Medicines, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Redwood City CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03634982
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Revolution Medicines, Inc.

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: Revolution Medicines, Inc. (0) Acquired (4)

aumolertinib (3 trials)

Lerociclib (2 trials)

letrozole (femara) (2 trials)

osimertinib (tagrisso) (1 trial)

Drugs in Phase 2 Trials (10)

Key: Revolution Medicines, Inc. (9) Acquired (1)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

cobimetinib (cotellic) (1 trial)

fulvestrant (faslodex) (1 trial)

pembrolizumab (keytruda) (2 trials)

pemetrexed (alimta) (1 trial)

rmc-4630 (3 trials)

rmc-6236 (2 trials)

rmc-6291 (2 trials)

sotorasib (LUMAKRAS) (1 trial)

Drugs in Phase 1 Trials (3)

rmc-5552 (2 trials)

rmc-9805 (1 trial)

sar442720 (1 trial)

Drugs in Other Trials (1)

Key: Revolution Medicines, Inc. (0) Acquired (1)

cs1001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 18